abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

이 페이지는 한국어로 제공되지 않으며 English로 표시됩니다.

기사

2017년 2월 10일

저자:
Martin Flanagan, The Scotsman UK

USA: 160 biotech companies join opposition to travel ban in open letter

“Biotech hits back over Trump travel ban Donald Trump's immigration ban has sparked protests around the world”, 9 February 2017

Chief executives of more than 160 biotech companies… put their Big Pharma counterparts to shame by protesting publicly about US President… Trump’s immigration ban. In an open letter…Nature… biotech bosses say they are “deeply concerned” and unequivocally opposed to the action. They say America’s status as the world’s “greatest developer of medicines” has been based on it sourcing top researchers, clinicians and executives from around the globe. [It] alludes to research…published [by] Nature…showing that in 2014 more than half of the 69,000 biomedical researchers working Stateside were born overseas. Symbolically, it places the biotech sector in the same camp as Silicon Valley tech giants...By contrast, most…pharmaceutical majors have decided that discretion is the better part of valour on the ban, whose legality may well end up in the US Supreme Court, for fear of making an enemy of the tweet-toothed President…[also refers to Google, Microsoft, Apple and Facebook].

타임라인